1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals Holding Co., Ltd

SHPMY
Shanghai Pharmaceuticals Holding Co., LtdUS flagOther OTC
7.08
USD
+0.67
- -
5.25BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
145.45
171.81
196.2
224.55
243.31
280.78
329.15
337.19
379.24
332.45
352.31
371.84
381.44
289.44
Basic EPS, GAAP
4.12
4.82
5.35
5.94
6.55
6.85
7.2
7.9
8.95
8.05
5.1
6.15
7.7
5.47
Free Cash Flow per Basic Share
0.13
0.08
-0.69
-0.32
1.19
2.1
5.77
6.74
1.66
2.95
3.06
4.63
5.15
-2.35
Dividend per Share
1.96
2.33
2.56
2.68
3.25
4.16
4.56
4.25
4.7
4.43
5.39
4.87
3.77
1.9
Book Value per Share
9.65
10.35
11.13
11.76
12.66
13.73
14.66
15.96
17.37
18.14
18.5
19.33
20.46
21.13
Tangible Book Value per Share
7.72
7.99
8.6
8.56
9.19
8.23
9.4
10.06
11.19
13.29
13.71
14.75
14.66
15.4
Basic Weighted Avg Shares
538
538
538
538
538
567
567
569
569
698
739
740
743
746
Sales/Revenue/Turnover
78,223
92,399
105,517
120,765
130,847
159,084
186,566
191,909
215,824
231,981
260,295
275,251
283,580
215,977
Operating Margin (%)
3.71
3.67
3.75
3.53
3.8
3.92
4.25
4.24
3.67
3.79
3.67
3.52
3.27
3.67
Depreciation Expense
550
585
673
746
840
1,169
1,885
2,138
2,140
2,222
2,187
2,419
2,862
- -
Net Income, GAAP
2,214
2,591
2,877
3,196
3,521
3,881
4,081
4,496
5,093
5,617
3,768
4,553
5,725
4,082
Effective Tax Rate (%)
19.48
21.26
19.36
17.45
22.04
16.6
22.86
21.88
22.95
20.62
26.76
26.81
28.98
25.5
Profit Margin (%)
2.83
2.8
2.73
2.65
2.69
2.44
2.19
2.34
2.36
2.42
1.45
1.65
2.02
1.89
Working Capital
16,812
16,656
16,159
19,154
19,010
24,568
23,484
19,430
24,670
38,822
40,062
45,785
45,266
47,960
LT Debt
125
105
93
2,836
2,959
9,600
10,290
2,685
8,592
7,561
7,336
9,728
5,385
4,751
Total Equity
29,001
31,099
33,808
36,834
39,676
46,433
49,386
54,741
59,066
78,002
80,326
83,742
89,787
92,786
Return on Invested Capital (%)
6.97
7.28
7.67
7.55
7.38
7.78
7.52
7.34
9.71
9.07
5.81
5.53
4.85
4.04
Return on Capital (%)
6.39
7.14
6.89
6.59
6.93
6.4
5.44
5.27
5.73
5.39
3.09
3.55
4.13
2.73
Return on Common Equity (%)
8.75
9.64
9.96
10.39
10.72
10.63
10.12
10.33
10.76
9.65
5.56
6.49
7.76
5.32

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46,901
48,871
48,232
LT Borrowings
4,236
3,257
3,277
LT Finance Leases
1,149
1,463
1,474
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,708
3,708
3,708
Market Capitalization
213,485
194,463
184,939

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
180,464
182,841
188,381
Cash, Cash Equivalents & STI
43,083
41,117
45,990
Accounts Receivable, Net
82,306
91,150
90,768
Inventories
45,359
41,682
42,685
Total Current Liabilities
135,198
136,509
140,422
Payables & Accruals
- -
- -
- -
ST Debt
46,901
48,871
48,232
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
10.88%
7.22%
Free Cash Flow
-13.17%
23.22%
11.73%
Net Income, GAAP
8.4%
7.44%
25.74%
Sales/Revenue/Turnover
10.54%
8.19%
3.03%
Total Cash Common Dividend
8.71%
4.63%
-22.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70,153
69,260
70,216
65,622
275,251
2025
70,763
70,830
- -
68,507
283,580
2026
75,262
72,208
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.1
- -
- -
- -
6.15
2025
1.8
- -
- -
- -
7.7
2026
1.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
- -
- -
- -
4.87
2025
0.55
- -
- -
- -
3.77
2026
0.9
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Qiuhua Yang
Full Time Employees
49,608
Sector
Healthcare
Industry
Medical - Distribution
Address
Shanghai Pharmaceutical Building Shanghai SH People's Republic of China 200020
IPO Date
Feb 19, 2014
Website
sphchina.com
Similar Companies
Everest Organics Limited (EVERESTO.BO)
LEOCLAN Co.,Ltd. (7681.T)
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
Vivo Bio Tech Limited (VIVOBIOT.BO)
Qingdao Baheal Medical Inc. (301015.SZ)
Paragon Care Limited (PGC.AX)
Business
Shanghai Pharmaceuticals Holding Co., Ltd. functions as a prominent investment holding enterprise, actively involved in the research, development, production, supply, and sale of pharmaceutical and healthcare products throughout the People's Republic of China and beyond. Its diverse operations are structured across key segments: Pharmaceutical Manufacturing, Distribution, Retail, and other healthcare services. The company's manufacturing arm develops a broad spectrum of products, encompassing modern chemical drugs, traditional Chinese medicines, biologicals, biochemicals, and medical devices. These offerings address a wide array of therapeutic areas, including oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, anti-infectives, immunological ailments, digestive and metabolic issues, and respiratory system health. With an annual output of approximately 700 distinct drug varieties, Shanghai Pharmaceuticals emphasizes innovative drug creation, advanced generics, and treatments for rare diseases. Significant investment is directed towards research and development, fostering an open innovation ecosystem that includes collaborations with academic and medical institutions. In the distribution sphere, the firm operates an extensive network for warehousing, logistics, and comprehensive supply chain solutions. These services cater to pharmaceutical producers and various dispensers, such as hospitals, other distributors, and retail pharmacies, offering value-added support like in-hospital supply chain management and direct drug delivery. Its retail segment manages a substantial chain of over 2,000 pharmacy outlets across 31 provinces, autonomous regions, and municipalities in China, alongside a growing online pharmaceutical platform. Additional services provided include consulting, asset management, clinical trial support, patient education, e-prescription management, and the development of remote healthcare solutions. Established in 1994 and headquartered in Shanghai, China, the company has grown to become a leading integrated pharmaceutical group. Recent strategic initiatives include accelerating the industrialization of cell therapy with partners, launching its first CAR-T product into clinical stages, and establishing a biomedical innovation incubation base. The company also engages in partnerships for innovative drug commercialization and has strengthened its distribution capabilities through acquisitions. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.